Author

R. K. Muir

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 1 Organism:mouse· 1 Organism:plant (other)· 1 Assay:proteomics· 1

Frequent Co-Authors

J. M. Bennett· 2 shared M. Bogyo· 2 shared S. Lovell· 2 shared A. Adibekian· 1 shared A. B. Olshen· 1 shared A. Renslo· 1 shared B. C. Hann· 1 shared B. Cerikan· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

J. M. Bennett

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets

J. M. Bennett, S. K. Narwal, S. Kabeche, D. Abegg, F. Hackett, T. Yeo, V. Li, R. K. Muir, F. F. Faucher, S. Lovell, M. Blackman, A. Adibekian, E. Yeh, D. A. Fidock, M. Bogyo

The paper identifies mixed alkyl/aryl phosphonates as anti-malarial compounds that inhibit serine hydrolases with low resistance potential.

Cell Chemical Biology · Sep 1, 2024Peer-reviewedMicrobiology

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19

K. Steuten, H. Kim, J. C. Widen, B. M. Babin, O. Onguka, S. Lovell, O. Bolgi, B. Cerikan, M. Cortese, R. K. Muir, J. M. Bennett, R. Geiss-Friedlander, C. Peters, R. Bartenschlager, M. Bogyo

This study evaluates compounds targeting SARS-CoV-2 proteases Mpro and PLpro, finding limited efficacy for Mpro due to off-target inhibition of host cathepsins and no viable hits for PLpro.

bioRxiv · Nov 21, 2020Microbiology

Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)

H. Jiang, R. K. Muir, R. L. Gonciarz, A. B. Olshen, I. Yeh, B. C. Hann, N. Zhao, Y.-h. Wang, J. Korkola, S. C. Behr, M. J. Evans, e. collisson, A. Renslo

This paper develops FeADCs, ferrous iron-activatable drug conjugates, to target KRAS-driven cancers with improved tumor selectivity and systemic tolerability.

bioRxiv · May 12, 2020Cancer Biology